Low-risk tumors demonstrated favorable immune infiltration (CD8+ T cells, M1 macrophages), higher tumor mutational burden (TMB), and greater immunogenicity, while high-risk tumors exhibited immune exclusion, cancer-associated fibroblast (CAF) enrichment, and adverse mutations. This evidence concerns the gene CD8A and neoplasm.